key: cord-0853339-e2k90ckg
authors: Yadav, Dipesh Kumar; Singh, Akanand; Zhang, Qi; Bai, Xueli; Zhang, Wei; Yadav, Rajesh Kumar; Singh, Alina; Zhiwei, Li; Adhikari, Vishnu Prasad; Liang, Tingbo
title: Involvement of liver in COVID-19: systematic review and meta-analysis
date: 2020-07-15
journal: Gut
DOI: 10.1136/gutjnl-2020-322072
sha: 7c26d94e7af1cbc61967c3b122767280c446e0fe
doc_id: 853339
cord_uid: e2k90ckg

nan

We have read with interest the recent study by Qi et al. 1 Currently, the impact of COVID-19 on the liver remains unexplored. Although majority of patients with COVID-19 have abnormal liver function, most studies on COVID-19 only attribute the severity of disease on the ground of respiratory complications. Thus, we aimed to perform a meta-analysis to estimate the prognosis of patients with COVID-19 stratified according to liver injury. Our metaanalysis includes nine studies 2-10 with a total of 2115 patients (online supplementary file).

Abnormal liver function in patients with COVID-19 is possibly multifactorial; that is, drug-induced liver injury (DILI), severe acute respiratory syndrome coronavirus 2 replications in the liver 10 and interorgan cross-talk in acute inflammation. 9 Published studies on COVID-19 have shown that 37.2%-76.3% of patients have abnormal liver function. 2 9 Similarly, the prevalence of liver injury is reported in about 21.5%-45.71% of patients. 2 10 Generally, 7.14%-64.15% of patients with COVID-19 had increased aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyltransferase (GGT) and bilirubin levels, whereas albumin was decreased to 27.9-33.0 g/L in nonsurvivor patients. 6 Besides, patients with COVID-19 with chronic liver disease (CLD) might develop decompensated liver as a systemic inflammatory response induced by COVID-19. 1 We found that the prevalence of CLD was 4% (95% CI 1.5 to 6.4, I 2 =89%) among patients with COVID-19, with cirrhosis and hepatitis B being the most common. Likewise, the incidence of liver injury was 27% (95% CI 18.2 to 35.8, I 2 =97%; figure 1). [2] [3] [4] [5] [6] [7] [8] [9] [10] Of note, older patients with COVID-19 had a higher risk of liver injury (standardised mean difference (SMD): 0.81, 95% CI 0.32 to 1.29, I 2 =85%, p=0.001).

Again, most patients with COVID-19 had a noticeable reduction in CD4 and CD8 counts. 9 In contrast, severe patients with COVID-19 had increased inflammatory markers like interleukin-6, erythrocyte sedimentation rate (ESR), D-dimer, ferritin, neutrophil counts and C reactive protein (CRP), suggesting a 'cytokine storm'. Concurrently, our meta-analysis showed a significantly lower absolute lymphocyte count (SMD: −0.81, 95% CI −1.22 to −0.41, I 2 =62%, p<0.0001) and higher ESR (SMD: 1.65, 95% CI 0.61 to 2.70, I 2 =90%, p=0.002) in the liver injury group compared with the non-liver injury group. However, no remarkable difference in CRP and absolute neutrophil count was observed between the two groups.

As evidence, DILI should not be overlooked in patients with COVID-19. Cai and colleagues found that the use of lopinavir/ritonavir was significantly associated with liver injury. 2 Contrarily, Fan et al did not find any difference in the prevalence of liver injury among patients with and without medication. 9 Our analysis found that the liver injury group had considerably more use of lopinavir/ ritonavir than the group without liver injury (OR: 4.15, 95% CI 2.36 to 7.29, I 2 =0%, p<0.00001). Meanwhile, insignificant difference was observed in the usage of other drugs.

Furthermore, we also examined the prognosis of patients with COVID-19 with liver injury, and we found that patients with liver injury had obviously more severe disease (OR: 2.57, 95% CI 1.25 to 5.26, I 2 =62%, p=0.01) and a higher prevalence of mortality (OR: 1.66, 95% CI: 1.04 to 2.64, I 2 =35%, p=0.03) (figure 2). [6] [7] [8] [9] However, length of hospital stay was not significantly different among the groups (SMD: −0.61, 95% CI −2.37 to 1.15, I 2 =98%, p=0.50). The overall rate of severity and mortality in patients with COVID-19 with liver injury was 53.5% (130/243) and 23.5% (42/179), 6-9 respectively.

To conclude, patients with COVID-19 have a high prevalence of liver injury, and patients with COVID-19 with liver injury are at an increased risk of severity and mortality. Thus, special attention should be given to any liver dysfunction while treating patients with COVID-19.

Xueli Bai http:// orcid. org/ 0000-0002-2934-0880 Tingbo Liang http:// orcid. org/ 0000-0003-0143-3353

Clinical course and risk factors for mortality of COVID-19 patients with preexisting cirrhosis: a multicentre cohort study

COVID-19: abnormal liver function tests

Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: a retrospective study

Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings

Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Clinical features of COVID-19-Related liver functional abnormality

Multicenter analysis of clinical characteristics and outcomes in patients with COVID-19 who develop liver injury